SPEDRA TABLET 50MG

MENARINI VON HEYDEN GMBH (GERMANY)🇸🇬 Health Sciences Authority

Approval Date: Jan 24, 2020
Approval ID: b894706c35fd333f
Company: MENARINI VON HEYDEN GMBH (GERMANY)
Type: Therapeutic

Approval Details

Approval Id: b894706c35fd333f
Drug Name: SPEDRA TABLET 50MG
Product Name: SPEDRA TABLET 50MG
Approval Number: SIN15880P
Approval Date: 2020-01-24
Registrant: A. MENARINI SINGAPORE PTE. LTD.
Licence Holder: A. MENARINI SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET
Dosage: 4.2 Posology and method of administration Posology Use in adult men The recommended dose is 100 mg taken as needed approximately 15 to 30 minutes before sexual activity (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Based on individual efficacy and tolerability, the dose may be increased to a maximum dose of 200 mg or decreased to 50 mg. The maximum recommended dosing frequency is once per day. Sexual stimulation is required for a response to treatment. Special populations Elderly (≥ 65 years old) Dose adjustments are not required in elder patients. Limited data are available in elder patients aged 70 years or above. Renal impairment Dose adjustments are not required in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 mL/min). Spedra is contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min) (see sections 4.3 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with mild or moderate renal impairment (creatinine clearance ≥30 mL/min but <80 mL/min) who were enrolled in phase 3 studies showed decreased efficacy compared to those with normal renal function. Hepatic impairment Spedra is contraindicated in patients with severe hepatic impairment (Child Pugh class C) (see sections 4.3 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with mild to moderate hepatic impairment (Child-Pugh class A or B) should initiate treatment with the minimum efficacious dose and adjust posology based on tolerance. Use in men with diabetes Dose adjustments are not required in diabetic patients. Paediatric population There is no relevant use of Spedra in the paediatric population in the indication of erectile dysfunction. Use in patients using other medicinal products Concomitant use of CYP3A4 inhibitors Co-administration of avanafil with potent CYP3A4 inhibitors (including ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir and telithromycin) is contraindicated (see sections 4.3, 4.4 and 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). In patients receiving concomitant treatment with moderate CYP3A4 inhibitors (including erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil), the maximum recommended dose of avanafil should not exceed 100 mg, with an interval of at least 48 hours between doses (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Method of administration For oral use. If Spedra is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Treatment of erectile dysfunction in adult men. In order for Spedra to be effective, sexual stimulation is required.
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Patients who are using any form of organic nitrate or nitric oxide donors (such as amyl nitrite) (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The co-administration of type 5 phosphodiesterase (PDE5) inhibitors, including avanafil, with guanylate cyclase stimulators, such as riociguat is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease before prescribing Spedra. The use of avanafil is contraindicated in: <ul class="dash"> <li>Patients who have suffered from a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months;</li> <li>Patients with resting hypotension (blood pressure < 90/50 mmHg) or hypertension (blood pressure > 170/100 mmHg);</li> <li>Patients with unstable angina, angina with sexual intercourse, or congestive heart failure categorised as New York Heart Association Class 2 or greater.</li> </ul> Patients with severe hepatic impairment (Child-Pugh C). Patients with severe renal impairment (creatinine clearance < 30 mL/min). Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with known hereditary degenerative retinal disorders. Patients who are using potent CYP3A4 inhibitors (including ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir and telithromycin) (see sections 4.2, 4.4 and 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Atc Code: G04BE10
Atc Item Name: avanafil
Pharma Manufacturer Name: A. MENARINI SINGAPORE PTE. LTD.

Active Ingredients

AVANAFIL

50MG

AVANAFIL

50 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 24, 2020

Approval ID

b894706c35fd333f

Type

Therapeutic

Back to HSA Approvals